| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Cyclohydrolase; folate metabolic pathway. Anhydroleucovorin is a substrate for cyclohydrolase, which converts it to 10-formyltetrahydrofolate. It is a form of tetrahydrofolate and plays a critical role in the folate metabolic cycle.
|
|---|---|
| ln Vitro |
Anhydroleucovorin is a substrate for cyclohydrolase, which converts it to 10-formyltetrahydrofolate. It is a key intermediate in the folate metabolic pathway. Its in vitro activity is related to its role as a folate derivative and substrate for folate-metabolizing enzymes.
|
| ln Vivo |
In vivo, anhydroleucovorin is the predominant, biologically active form of vitamin B9 (folate) utilized by the body for vital cellular functions. It is a key intermediate in the folate metabolic cycle and is used as a starting material for the synthesis of leucovorin.
|
| Enzyme Assay |
Non-cell-based assays for anhydroleucovorin include enzymatic assays measuring its conversion to 10-formyltetrahydrofolate by cyclohydrolase. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization and purity assessment.
|
| Cell Assay |
Cell-based assays for anhydroleucovorin use cell lines to study folate metabolism. The compound's effects on cellular folate levels and one-carbon metabolism can be assessed. It may be used in studies of folate-dependent enzyme activity.
|
| Animal Protocol |
In vivo studies of anhydroleucovorin are related to its role in folate metabolism and as a precursor for leucovorin synthesis. Animal models may be used to study folate metabolism and the pharmacokinetics of folate derivatives.
|
| ADME/Pharmacokinetics |
Anhydroleucovorin has a molecular formula of C₂₀H₂₁N₇O₆ and a molecular weight of 455.43 g/mol. It is a form of tetrahydrofolate and a key intermediate in the folate metabolic cycle. It is a substrate for cyclohydrolase, which converts it to 10-formyltetrahydrofolate. It is used as a starting material for the synthesis of leucovorin.
|
| Toxicity/Toxicokinetics |
Anhydroleucovorin is generally considered to have low toxicity as a folate derivative. Standard laboratory safety practices should be followed when handling this compound.
|
| References |
[1]. M J OSBORN, et al. Participation of anhydroleucovorin in the hydroxymethyl tetrahydrofolic dehydrogenase system. Biochim Biophys Acta,1957,26, 3.
[2]. K Motycka, et al. Localized chemotherapy of Gardner's lymphosarcoma of C3H mice using combinations of carrier-sorbed antifolics and detoxicating tetrahydrofolates. Czech Med,1981,4, 1. |
| Additional Infomation |
Anhydroleucovorin is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain).
Anhydroleucovorin (5,10-Methenyltetrahydrofolate) is a form of tetrahydrofolate and a pivotal intermediate in the folate metabolic cycle. It is a substrate for cyclohydrolase, which converts it to 10-formyltetrahydrofolate. The compound is the predominant, biologically active form of vitamin B9 (folate) utilized by the body for vital cellular functions. It is also a key starting material in the synthesis of the chemoprotectant drug leucovorin. It is for research use only. |
| Molecular Formula |
C20H21N7O6
|
|---|---|
| Molecular Weight |
455.42
|
| Exact Mass |
456.163
|
| CAS # |
7444-29-3
|
| PubChem CID |
135450599
|
| Appearance |
Light yellow to green yellow solid powder
|
| LogP |
0.52
|
| Hydrogen Bond Donor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
960
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C1NC(N)=NC2NC[C@]3([H])C[N+](C4C=CC(C(=O)N[C@H](C(=O)[O-])CCC(=O)O)=CC=4)=CN3C1=2
|
| InChi Key |
MEANFMOQMXYMCT-OLZOCXBDSA-N
|
| InChi Code |
InChI=1S/C20H21N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,9,12-13H,5-8H2,(H6-,21,22,23,24,25,28,29,30,31,32,33)/t12-,13+/m1/s1
|
| Chemical Name |
(2S)-2-[[4-[(6aR)-3-amino-1-oxo-5,6,6a,7-tetrahydro-2H-imidazo[1,5-f]pteridin-10-ium-8-yl]benzoyl]amino]-5-hydroxy-5-oxopentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1958 mL | 10.9789 mL | 21.9578 mL | |
| 5 mM | 0.4392 mL | 2.1958 mL | 4.3916 mL | |
| 10 mM | 0.2196 mL | 1.0979 mL | 2.1958 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
